- Home
- SAVA vs PETS Comparison
SAVA vs PETS Comparison
Compare SAVA & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- PETS
- Stock Information
- Founded
- SAVA 1998
- PETS 1996
- Country
- SAVA United States
- PETS United States
- Employees
- SAVA N/A
- PETS N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- PETS Retail-Drug Stores and Proprietary Stores
- Sector
- SAVA Health Care
- PETS Consumer Staples
- Exchange
- SAVA Nasdaq
- PETS Nasdaq
- Market Cap
- SAVA 70.5M
- PETS 62.8M
- IPO Year
- SAVA N/A
- PETS N/A
- Fundamental
- Price
- SAVA $1.99
- PETS $3.25
- Analyst Decision
- SAVA Buy
- PETS Sell
- Analyst Count
- SAVA 3
- PETS 2
- Target Price
- SAVA $54.50
- PETS $3.35
- AVG Volume (30 Days)
- SAVA 1.1M
- PETS 128.9K
- Earning Date
- SAVA 08-07-2025
- PETS 08-05-2025
- Dividend Yield
- SAVA N/A
- PETS N/A
- EPS Growth
- SAVA N/A
- PETS N/A
- EPS
- SAVA N/A
- PETS 0.02
- Revenue
- SAVA N/A
- PETS $247,010,000.00
- Revenue This Year
- SAVA N/A
- PETS N/A
- Revenue Next Year
- SAVA N/A
- PETS N/A
- P/E Ratio
- SAVA N/A
- PETS $192.80
- Revenue Growth
- SAVA N/A
- PETS N/A
- 52 Week Low
- SAVA $1.15
- PETS $2.90
- 52 Week High
- SAVA $42.20
- PETS $6.85
- Technical
- Relative Strength Index (RSI)
- SAVA 51.90
- PETS 36.65
- Support Level
- SAVA $1.76
- PETS $3.13
- Resistance Level
- SAVA $2.17
- PETS $3.40
- Average True Range (ATR)
- SAVA 0.10
- PETS 0.17
- MACD
- SAVA -0.02
- PETS -0.03
- Stochastic Oscillator
- SAVA 55.95
- PETS 21.05
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.